Download PDF
Semin Thromb Hemost 2011; 37(1): 041-048
DOI: 10.1055/s-0030-1270070
© Thieme Medical Publishers

The Influence of Pituitary, Adrenal, and Parathyroid Hormones on Hemostasis and Thrombosis

Alessandro Squizzato1 , 2 , Bregje Van Zaane2 , 3 , Victor E.A Gerdes2 , 3 , Harry R. Büller2
  • 1Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical Medicine, University of Insubria, Varese, Italy
  • 2Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
  • 3Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
19 January 2011 (online)

    Permissions and Reprints

ABSTRACT

Endocrine disorders can influence the hemostatic balance. Abnormal coagulation test results have been observed in patients with abnormal hormone levels. The present review updates the available evidence on the influence of pituitary, adrenal, and parathyroid hormones on the coagulation and the fibrinolytic system, and their possible clinical implications. The literature supports a possible relevant clinical effect of the imbalance between coagulation and fibrinolysis on thrombotic events in endogenous Cushing's syndrome. An effect on markers of coagulation and fibrinolysis has been shown for hyperprolactinemia, growth hormone excess or deficiency, exogenous hypercortisolism, pheochromocytoma, primary hyperaldosteronism, and hyperparathyroidism. However, the clinical relevance is still unproven. Until definitive evidence is available, clinicians should be aware of the possibility that endocrine disorders may be risk factors for thrombotic events.

KEYWORDS

Coagulation - hypercortisolism - prolactin - growth hormone - parathyroid - bleeding - thrombosis

REFERENCES

  • 1 Squizzato A, Gerdes V E, Ageno W, Büller H R. The coagulation system in endocrine disorders: a narrative review.  Intern Emerg Med. 2007;  2 (2) 76-83
    CrossrefPubMedGoogle Scholar
  • 2 Franchini M, Lippi G, Manzato F, Vescovi P P, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders.  Eur J Endocrinol. 2010;  162 (3) 439-451
    CrossrefPubMedGoogle Scholar
  • 3 Atmaca A, Gurlek A, Dagdelen S et al.. Hyperprolactinemia of pregnancy is not associated with increased in vivo platelet activity and shortened in vitro bleeding times.  Exp Clin Endocrinol Diabetes. 2006;  114 (4) 188-191
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Wallaschofski H, Lohmann T, Hild E et al.. Enhanced platelet activation by prolactin in patients with ischemic stroke.  Thromb Haemost. 2006;  96 (1) 38-44
    PubMedGoogle Scholar
  • 5 Reuwer A Q, Nieuwland R, Fernandez I et al.. Prolactin does not affect human platelet aggregation or secretion.  Thromb Haemost. 2009;  101 (6) 1119-1127
    PubMedGoogle Scholar
  • 6 Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.  Clin Endocrinol (Oxf). 2009;  December 18 (Epub ahead of print
    PubMedGoogle Scholar
  • 7 Devin J K, Blevins Jr L S, Verity D K et al.. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency.  J Clin Endocrinol Metab. 2007;  92 (9) 3633-3639
    CrossrefPubMedGoogle Scholar
  • 8 Erem C, Nuhoglu I, Kocak M et al.. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.  Endocrine. 2008;  33 (3) 270-276
    CrossrefPubMedGoogle Scholar
  • 9 Gómez J M, Sahún M, Vila R et al.. Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency.  Clin Endocrinol (Oxf). 2006;  64 (6) 632-639
    CrossrefPubMedGoogle Scholar
  • 10 Gómez J M, Sahún M, Vila R et al.. Elevation of E-selectin concentrations may correlate with potential endothelial dysfunction in individuals with hypopituitarism during therapy with growth hormone.  Curr Neurovasc Res. 2007;  4 (1) 55-62
    CrossrefPubMedGoogle Scholar
  • 11 Miljic D, Miljic P, Doknic M et al.. Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults.  Hormones (Athens). 2006;  5 (3) 187-191
    CrossrefPubMedGoogle Scholar
  • 12 Van Zaane B, Nur E, Squizzato A et al.. Hypercoagulable state in Cushing's syndrome: a systematic review.  J Clin Endocrinol Metab. 2009;  94 (8) 2743-2750
    CrossrefPubMedGoogle Scholar
  • 13 Erem C, Nuhoglu I, Yilmaz M et al.. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.  J Endocrinol Invest. 2009;  32 (2) 169-174
    CrossrefPubMedGoogle Scholar
  • 14 Kastelan D, Dusek T, Kraljevic I et al.. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers.  Endocrine. 2009;  36 (1) 70-74
    CrossrefPubMedGoogle Scholar
  • 15 Casonato A, Daidone V, Sartorello F et al.. Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome.  Br J Haematol. 2008;  140 (2) 230-235
    CrossrefPubMedGoogle Scholar
  • 16 Baranyai R, Nonell A, Deuschle M, Lederbogen F. How depression may increase cardiac risk: effect of hypercortisolism on platelet activation markers: preliminary data.  Neuropsychobiology. 2008;  57 (3) 146-150
    CrossrefPubMedGoogle Scholar
  • 17 Eggers A E. Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke.  Med Hypotheses. 2006;  67 (5) 1065-1071
    CrossrefPubMedGoogle Scholar
  • 18 Erem C, Kocak M, Hacihasanoglu A, Yilmaz M, Saglam F, Ersoz H O. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.  Exp Clin Endocrinol Diabetes. 2008;  116 (10) 619-624
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.  Eur J Endocrinol. 2009;  160 (5) 863-868
    CrossrefPubMedGoogle Scholar
  • 20 Chertok-Shacham E, Ishay A, Lavi I, Luboshitzky R. Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism.  Med Sci Monit. 2008;  14 628-632
    PubMedGoogle Scholar
  • 21 Raaz D, Wallaschofski H, Stumpf C et al.. Increased prolactin in acute coronary syndromes as putative co-activator of ADP-stimulated P-selectin expression.  Horm Metab Res. 2006;  38 (11) 767-772
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Verhelst J, Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults.  Eur J Endocrinol. 2009;  161 ((Suppl 1) S41-S49
    CrossrefPubMedGoogle Scholar
  • 23 Melmed S. Medical progress: acromegaly.  N Engl J Med. 2006;  355 (24) 2558-2573
    CrossrefPubMedGoogle Scholar
  • 24 Newell-Price J, Bertagna X, Grossman A B, Nieman L K. Cushing's syndrome.  Lancet. 2006;  367 (9522) 1605-1617
    CrossrefPubMedGoogle Scholar
  • 25 Dekkers O M, Biermasz N R, Pereira A M et al.. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma.  J Clin Endocrinol Metab. 2007;  92 (3) 976-981
    CrossrefPubMedGoogle Scholar
  • 26 Etxabe J, Vazquez J A. Morbidity and mortality in Cushing's disease: an epidemiological approach.  Clin Endocrinol (Oxf). 1994;  40 (4) 479-484
    CrossrefPubMedGoogle Scholar
  • 27 Albiger N, Testa R M, Almoto B et al.. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors.  Horm Metab Res. 2006;  38 (6) 405-410
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Geerts W H, Bergqvist D, Pineo G F American College of Chest Physicians et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 ((6, Suppl)) 381S-453S
    CrossrefPubMedGoogle Scholar
  • 29 van Staa T P, Leufkens H G, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom.  QJM. 2000;  93 (2) 105-111
    CrossrefPubMedGoogle Scholar
  • 30 Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P, Blann A D. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men.  Thromb Haemost. 2005;  94 (4) 797-801
    PubMedGoogle Scholar
  • 31 Brotman D J, Girod J P, Posch A et al.. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers.  Thromb Res. 2006;  118 (2) 247-252
    CrossrefPubMedGoogle Scholar
  • 32 Darmon P, Dadoun F, Boullu-Ciocca S, Grino M, Alessi M C, Dutour A. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity.  Am J Physiol Endocrinol Metab. 2006;  291 (5) E995-E1002
    CrossrefPubMedGoogle Scholar
  • 33 Dover A R, Hadoke P W, Walker B R, Newby D E. Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans.  J Cardiovasc Pharmacol. 2007;  50 (3) 321-326
    CrossrefPubMedGoogle Scholar
  • 34 Lewis G P, Piper P J. Inhibition of release of prostaglandins as an explanation of some of the actions of anti-inflammatory corticosteroids.  Nature. 1975;  254 (5498) 308-311
    CrossrefPubMedGoogle Scholar
  • 35 Moraes L A, Paul-Clark M J, Rickman A, Flower R J, Goulding N J, Perretti M. Ligand-specific glucocorticoid receptor activation in human platelets.  Blood. 2005;  106 (13) 4167-4175
    CrossrefPubMedGoogle Scholar
  • 36 Souverein P C, Berard A, Van Staa T P et al.. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.  Heart. 2004;  90 (8) 859-865
    CrossrefPubMedGoogle Scholar
  • 37 Wei L, MacDonald T M, Walker B R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease.  Ann Intern Med. 2004;  141 (10) 764-770
    CrossrefPubMedGoogle Scholar
  • 38 Calvo-Alén J, Toloza S M, Fernández M LUMINA Study Group et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.  Arthritis Rheum. 2005;  52 (7) 2060-2068
    CrossrefPubMedGoogle Scholar
  • 39 Stolz E, Klötzsch C, Schlachetzki F, Rahimi A. High-dose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis.  Eur Neurol. 2003;  49 (4) 247-248
    CrossrefPubMedGoogle Scholar
  • 40 Yale S H, Medlin S C, Liang H, Peters T, Glurich I, Mazza J J. Risk assessment model for venothromboembolism in post-hospitalized patients.  Int Angiol. 2005;  24 (3) 250-254
    PubMedGoogle Scholar
  • 41 Gaab M R, Trost H A, Alcantara A German Ultrahigh Dexamethasone Head Injury Study Group et al. “Ultrahigh” dexamethasone in acute brain injury. Results from a prospective randomized double-blind multicenter trial (GUDHIS).  Zentralbl Neurochir. 1994;  55 (3) 135-143
    PubMedGoogle Scholar
  • 42 Høgevold H E, Høiseth A, Reikerås O. Effect of high-dose corticosteroids on the incidence of deep vein thrombosis after total hip replacement.  Arch Orthop Trauma Surg. 1991;  111 (1) 29-31
    CrossrefPubMedGoogle Scholar
  • 43 Sartori M T, Rigotti P, Marchini F et al.. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy.  Transplantation. 2003;  75 (7) 994-998
    PubMedGoogle Scholar
  • 44 van de Wyngaert F A, Beguin C, D'Hooghe M B et al.. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.  Acta Neurol Belg. 2001;  101 (4) 210-216
    PubMedGoogle Scholar
  • 45 Bottles K D, Morrissey J H. Dexamethasone enhances agonist induction of tissue factor in monocytes but not in endothelial cells.  Blood Coagul Fibrinolysis. 1993;  4 (3) 405-414
    CrossrefPubMedGoogle Scholar
  • 46 Reddy K V, Bhattacharjee G, Schabbauer G et al.. Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability.  J Leukoc Biol. 2004;  76 (1) 145-151
    CrossrefPubMedGoogle Scholar
  • 47 van Zonneveld A J, Curriden S A, Loskutoff D J. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter.  Proc Natl Acad Sci U S A. 1988;  85 (15) 5525-5529
    CrossrefPubMedGoogle Scholar
  • 48 Yamamoto Y, Ishizu A, Ikeda H, Otsuka N, Yoshiki T. Dexamethasone increased plasminogen activator inhibitor-1 expression on human umbilical vein endothelial cells: an additive effect to tumor necrosis factor-alpha.  Pathobiology. 2004;  71 (6) 295-301
    CrossrefPubMedGoogle Scholar
  • 49 Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study.  J Clin Endocrinol Metab. 2006;  91 (12) 4849-4853
    CrossrefPubMedGoogle Scholar
  • 50 van den Akker E L, Koper J W, van Rossum E F et al.. Glucocorticoid receptor gene and risk of cardiovascular disease.  Arch Intern Med. 2008;  168 (1) 33-39
    CrossrefPubMedGoogle Scholar
  • 51 Zhou W, Ding S F. Concurrent pheochromocytoma, ventricular tachycardia, left ventricular thrombus, and systemic embolization.  Intern Med. 2009;  48 (12) 1015-1019
    CrossrefPubMedGoogle Scholar
  • 52 von Känel R, Dimsdale J E. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo.  Eur J Haematol. 2000;  65 (6) 357-369
    CrossrefPubMedGoogle Scholar
  • 53 Hoppener M R, Kraaijenhagen R A, Hutten B A, Büller H R, Peters R JG, Levi M. Beta-receptor blockade decreases elevated plasma levels of factor VIII:C in patients with deep vein thrombosis.  J Thromb Haemost. 2004;  2 (8) 1316-1320
    CrossrefPubMedGoogle Scholar
  • 54 Shulkin B L, Shapiro B, Sisson J C. Pheochromocytoma, polycythemia, and venous thrombosis.  Am J Med. 1987;  83 (4) 773-776
    CrossrefPubMedGoogle Scholar
  • 55 Grant P J. Hormonal regulation of the acute haemostatic response to stress.  Blood Coagul Fibrinolysis. 1990;  1 (3) 299-306
    CrossrefPubMedGoogle Scholar
  • 56 Ganguly A. Primary aldosteronism.  N Engl J Med. 1998;  339 (25) 1828-1834
    CrossrefPubMedGoogle Scholar
  • 57 Milliez P, Girerd X, Plouin P F, Blacher J, Safar M E, Mourad J J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.  J Am Coll Cardiol. 2005;  45 (8) 1243-1248
    Google Scholar
  • 58 Vaughan D E, Lazos S A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.  J Clin Invest. 1995;  95 (3) 995-1001
    CrossrefPubMedGoogle Scholar
  • 59 Brown N J, Agirbasli M A, Williams G H, Litchfield W R, Vaughan D E. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.  Hypertension. 1998;  32 (6) 965-971
    CrossrefPubMedGoogle Scholar
  • 60 Oikawa T, Freeman M, Lo W, Vaughan D E, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.  Kidney Int. 1997;  51 (1) 164-172
    CrossrefPubMedGoogle Scholar
  • 61 Ducros E, Berthaut A, Mirshahi S S et al.. Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium.  Biochem Biophys Res Commun. 2008;  373 (2) 192-196
    CrossrefPubMedGoogle Scholar
  • 62 Celi A, Del Fiorentino A, Cianchetti S, Pedrinelli R. Tissue factor modulation by angiotensin II: a clue to a better understanding of the cardiovascular effects of renin-angiotensin system blockade?.  Endocr Metab Immune Disord Drug Targets. 2008;  8 (4) 308-313
    CrossrefPubMedGoogle Scholar
  • 63 Asselbergs F W, Williams S M, Hebert P R et al.. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.  Thromb Haemost. 2006;  96 (4) 471-477
    PubMedGoogle Scholar
  • 64 Asselbergs F W, Williams S M, Hebert P R et al.. Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.  Genomics. 2007;  89 (3) 362-369
    CrossrefPubMedGoogle Scholar
  • 65 Asselbergs F W, Williams S M, Hebert P R et al.. The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context.  Hum Genet. 2007;  122 ((3-4)) 275-281
    CrossrefPubMedGoogle Scholar
  • 66 Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function.  Am J Hypertens. 2006;  19 (12) 1293-1299
    CrossrefPubMedGoogle Scholar
  • 67 Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study.  BMJ. 2006;  333 (7563) 330
    CrossrefPubMedGoogle Scholar
  • 68 Walker M D, Silverberg S J. Cardiovascular aspects of primary hyperparathyroidism.  J Endocrinol Invest. 2008;  31 (10) 925-931
    PubMedGoogle Scholar
  • 69 Hagström E, Hellman P, Larsson T E et al.. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.  Circulation. 2009;  119 (21) 2765-2771
    CrossrefPubMedGoogle Scholar
  • 70 Walker M D, Fleischer J, Rundek T et al.. Carotid vascular abnormalities in primary hyperparathyroidism.  J Clin Endocrinol Metab. 2009;  94 (10) 3849-3856
    CrossrefPubMedGoogle Scholar
  • 71 Viganò G, Gotti E, Comberti E, Giangrande A, Trevisan R, Remuzzi G. Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure.  Nephrol Dial Transplant. 1989;  4 (11) 971-974
    PubMedGoogle Scholar
  • 72 Leithner C, Kovarik J, Sinzinger H, Woloszczuk W. Parathyroid hormone does not inhibit platelet aggregation.  Lancet. 1984;  1 (8373) 367-368
    PubMedGoogle Scholar
  • 73 Targher G, Pichiri I, Zoppini G, Bonora E, Chonchol M. Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review.  Semin Thromb Hemost. 2009;  35 (7) 605-612
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 van Zaane B, Reuwer A Q, Büller H R, Kastelein J J, Gerdes V E, Twickler M T. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?.  Semin Thromb Hemost. 2009;  35 (5) 478-487
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet. 1999;  353 (9159) 1167-1173
    CrossrefPubMedGoogle Scholar

Alessandro SquizzatoM.D. 

Medicina Interna 1, Ospedale di Circolo

viale Borri, 57, 21100 Varese, Italy

Email: alexsquizzo@libero.it